Longhorn is developing novel, industry-changing solutions to better diagnose, prevent, and monitor disease.
We are a Veteran and family owned One Health company addressing human and animal public health concerns worldwide.
Longhorn’s investment in the invention, development, and US regulatory approval process of PrimeStore MTM, the original Molecular Transport Media and the US FDA predicate device, was crucial to the initial response to the SARS-CoV-2 sample collection shortage providing crucial supplies to all 50 states. As a trusted partner with government agencies and healthcare organizations at all levels, we develop novel vaccines and diagnostics tools to help achieve optimal health outcomes in humans and animals alike.
Recent News
The Longhorn Difference
Proven innovation for a global difference.
Taking a robust approach to solving the world's biggest challenges, we develop transformational solutions for use in any climate or socio-economic infrastructure.
Evaluated by national
and international agencies.
Core Diagnostic Product
PrimeStore® MTM is the original Molecular Transport Media for pathogen inactivation, stabilization, and molecular testing sensitivity.
PrimeStore MTM is a globally trusted predicate device, invented and patented in 2007 to safely and efficiently transport RNA/DNA, even under the most challenging conditions. As the original (De Novo) MTM, it was fully optimized to inactivate pathogens and preserve RNA, mRNA & DNA for safer, more efficient, cost-effective sample testing.
This device was a critical component in controlling the Covid-19 pandemic and saving lives around the world.
Core Vaccine Product
LHNVD-105 is designed to be the most comprehensive universal influenza vaccine ever produced.
Targeting both cellular and humoral immunity, LHNVD-105 is a combination of multiple epitopes across HA, NA, and M2e as well as attached T-cell epitopes. This composite peptide is adjuvanted with the U.S. Army's next generation breakthrough adjuvant AFLQ.
Phase I clinical trials of LHNVD-105 are expected to begin in mid-2023.
Product Portfolio
Diagnostic Tools
Innovation in molecular testing.
-
PrimeStore MTM
The patented, FDA-cleared Class II sample collection and transport device for inactivating pathogens and preserving DNA/RNA.
-
Salorn STM
The virucidal, bacteriostatic, guanidine-free sample collection device for highly sensitive antigen testing capabilities.
-
PrimeScreen MTB™
The original tuberculosis triage oral screening kit that detects MTB DNA in the oral cavity for further diagnostic and clinical evaluation.
-
PrimeSeqMDR
The uniquely optimized blend of primers, buffers, and enzymes for full-length amplification of MTB resistance genes.
-
PrimeXtract™
The most efficient spin column-based total nucleic extraction system for sensitive purification of RNA.
Vaccines & Antibodies
Infectious disease prevention and protection.
-
Composite Peptide Vaccines
A transformational vaccine platform taking on the world’s biggest healthcare challenges.
-
Monoclonal Antibodies
Antibodies for tackling multi-drug antibiotic resistance.
